Introduction
Peroxisome proliferator chemicals (PPs) represent a large and structurally diverse group of agents including fibrate hypolipidemic drugs, phthalate ester plasticizers and herbicides, with a high likelihood of clinical, occupational and environmental exposure to humans (1) . Exposure of rodents to PPs results in pleiotropic responses including hepatomegaly, proliferation of peroxisomes and induction of genes encoding mitochondrial, peroxisomal and microsomal fatty acid oxidation enzymes (2) (3) (4) (5) . In addition, although PPs have not been shown to act as genotoxic carcinogens, long-term treatment of rats and mice with PPs results in 100% incidence of hepatocellular carcinomas (5) (6) (7) .
An increased understanding of the mechanism underlying the effects of PPs was initiated by identification of the nuclear receptor known as peroxisome proliferator-activated receptor a (PPARa) (8) . Binding and activation of PPARa by PPs are essential for induction of peroxisome proliferation and fatty acid metabolizing enzymes, hepatomegaly and ultimately liver cancer after prolonged exposure of PPs to rodents. PPARa is a member of the nuclear hormone receptor superfamily and three PPAR (a, b and c) genes were identified that are expressed in different tissues or organs. Among the three, PPARa is mainly expressed in liver, kidney and heart. PPARs function as transcription factors through the classic ligand-dependent nuclear hormone receptor mechanism. Upon binding to their ligands, PPARs undergo conformational changes that allow co-repressor release and co-activator recruitment, heterodimerization with retinoid X receptor, and selective binding to specific DNA sequences termed peroxisome proliferator response elements in the promoters of target genes. PPARa serves a fundamental role in mammals by acting as a central modulator of signaling molecules that mediate changes in gene expression to maintain lipid homeostasis. In addition, PPARa has also been linked to the regulation of genes important in cell growth and differentiation (9, 10) .
Use of the Ppara-null mouse model revealed that PPARa is responsible for PP-induced pleiotropic responses, including the development of hepatocellular carcinoma in mice, as these null mice were refractory to all known PP-induced pleiotropic responses including peroxisome proliferation, hepatomegaly and hepatocellular carcinomas (11, 12) . While carcinogenesis is a complicated multistage process, the induction of oxidative stress and lipid peroxidation, increase in hepatocyte proliferation and/or decrease in apoptosis are central components of the cascade of molecular events leading to liver tumors in rodents fed PPs (5) . However, the link between PPARa and hepatocarcinogenesis in rodents at the molecular and cellular level is not fully understood. To clarify whether activation of PPARa only in hepatocytes is sufficient to the induction of hepatic neoplasia and whether non-parenchymal hepatic cells contribute to the carcinogenesis process, the potent viral transcriptional activator VP16 was fused to the mouse PPARa cDNA to create a transcription factor that constitutively activates PPARa-responsive genes in the absence of ligands. Transgenic mice were produced whereby inducible expression of the VP16PPARa transgene was targeted to hepatocytes using the tetracycline regulatory system under the control of the liverenriched activator protein (LAP or cEBPb) promoter (13, 14) to determine whether activation of PPARa in hepatocytes can produce the same hepatic responses as PPARa ligand treatment in mouse. In comparison with wild-type (Wt) mice treated with the potent PPARa ligand Wy-14,643, LAP-VP16PPARa mice exhibited significantly decreased serum triglycerides and free fatty acids, peroxisome proliferation and marked induction of PPARa target genes encoding fatty acid b-oxidation enzymes. However, the VP16PPARa transgenic mice at 1 year of age exhibited no gross or microscopic evidence of either preneoplastic hepatic lesions or hepatocellular neoplasia.
Materials and methods

Generation of transgenic mice
The tetracycline response element promoter-driving expression of the VP16PPARa fusion protein were recently generated (15) . Briefly, the potent viral transcriptional activator VP16 was fused to the mouse PPARa cDNA to create a transcription factor that constitutively activates PPARa-responsive genes in the absence of ligand. The single-transgenic mice were generated with the VP16PPARa fused to the tetracycline response element (TREVP16PPARa) (14) . Subsequently, double-transgenic (LAP-VP16PPARa) mice were produced by breeding with LAP/tetracycline-controlled transactivator (tTA) transgenic mice expressing the tTA transgene under the control of the LAP or cEBPb promoter (13, 14) to reconstitute the tetracycline-responsive regulatory system (16, 17) . TREVP16PPARa mice and LAP/tTA transgenic mice behaved similar to Wt mice throughout the study. Therefore, mice with these three genotypes were grouped together as control littermates unless otherwise specified. Mice expressing both transgenes were subsequently bred into the 129/Sv strain background for at least four generations. The transgenic animals were screened by Southern blot analysis or polymerase chain reaction (PCR) of tail DNA. The primers for the transgene VP16PPARa, tTA and mouse endogenous PPARa were described previously (14, 15, 18 
Serum lipids
For serum analysis, mice were deprived of food for 16 h, blood collected and then returned to the appropriate diet for an additional 3 days before they were killed. Serum total triglycerides and free fatty acid were measured using a commercial kit (Sigma, St Louis, MO).
Palmitoyl-CoA oxidation
The liver homogenates in 20% sucrose were centrifuged at 600g for 10 min. The resulting supernatant was centrifuged at 10 000g for 10 min to yield a subcellular fraction containing primarily mitochondria, peroxisomes and lysosomes. Palmitoyl-CoA oxidation was measured in this subcellular fraction as the reduction of NAD þ at 340 nm in the presence of KCN as an inhibitor of mitochondrial b-oxidation (2, 19) .
Determination of liver lipid content
Liver triglyceride and cholesterol contents were determined using the procedures described previously (20) .
Hepatocyte proliferation and apoptosis
For determination of cell proliferation using 5-bromo-2#-deoxyuridine (BrdU), mice were anesthetized with 2.5% avertin and implanted subcutaneously with an osmotic pump (Alzet model 2001, 1 ll/h DURECT Corporation, Cupertino, CA) containing 200 ll of 16 mg/ml BrdU (Sigma). After 1 week of receiving the respective diet, the mice were killed by overexposure to carbon dioxide, livers removed and weighed and sections from both the left and median lobes were obtained and fixed in 10% phosphate-buffered formalin (Fisher scientific, Fair Lawn, NJ). Sections from the duodenum were also obtained and fixed in phosphate-buffered formalin. The duodenum sample was used to verify uniform flow of BrdU up to the time the animals were killed. Apoptosis in hepatocytes was analyzed by using terminal deoxynucleotidyl transferasemediated dUTP nick end labeling (Promega Corporation, Madison, WI) as described previously (14) .
Histological analyses
Mice were killed by overexposure to carbon dioxide and the livers were excised, fixed in 10% neutral-buffered formalin (Fisher Scientific), embedded in paraffin and 4-6 lm sections were prepared. Sections were stained with hematoxylin and eosin (H & E), and were evaluated by light microscopy.
Immunochemistry
Immunostaining for the VP16 tag was performed using polyclonal antibodies (Abcam, Cambridge, MA) and detected by use of the ABC-kit (Vector Laboratory, Burlingame, CA). Immunostaining for BrdU (DakoCytomation, Carpinteria, CA) was performed using monoclonal antibody, which was labeled with biotin by ARK kit (DakoCytomation) prior to application to tissues. In brief, sections were washed in phosphate-buffered saline (PBS) and incubated in 0.3% hydrogen peroxide in 100% methanol for 30 min at room temperature. The sections were then incubated in citrate buffer (pH 6.0) at 100°C for 10 min. After washing in PBS, the sections were blocked in PBS containing 5% skim milk at room temperature for 30 min. The sections were then rinsed and incubated sequentially with primary antibody (diluted 1:100 in PBS containing 1% bovine serum albumin) for 2 h at room temperature, biotinylated goat antirabbit immunoglobulin G (diluted 1:50 in PBS containing 1% bovine serum albumin) for 30 min (when polyclonal antibody was used as the primary antibody) and avidin-biotinylated peroxidase complex (Vector Laboratory) in PBS for 30 min. The bound antibody was visualized by 3,3#-diaminobenzidine as a peroxidase substrate. Sections were rinsed in water, counterstained with hematoxylin (Sigma), dehydrated and mounted in permanent mounting medium. The BrdU labeling index was determined by counting at least 1500 nuclei per slide (at random high-power fields; magnification 300Â) and calculated as 100% Â (number of stained hepatocyte nuclei/total number of stained þ unstained hepatocyte nuclei).
Northern blot analysis
Total RNA was isolated by mechanical disruption of liver tissue in Trizol reagent (Invitrogen, Carlsbad, CA) following the manufacturer's protocol. The concentration of RNA was determined by spectrophotometry. Northern blot analysis was carried out as described previously (21) . Briefly, 10 lg of total RNA was electrophoresed on a 1.0% agarose gel containing 0.22 M formaldehyde, transferred to a nylon membrane and cross-linked by ultraviolet light exposure. Membranes were hybridized in ULTRAhyb buffer (Ambion, Austin, TX) with random primer 32 P-labeled cDNA probes (21, 22) following the manufacturer's protocol, and washed with salt/detergent solution using standard procedures.
Quantitative real-time PCR Real-time PCR reactions were carried out using SYBR Green PCR master mix (AB Applied Biosystems, Warrington, UK) and the ABI PRISM 7900 HT Sequence Detection System (AB Applied Biosystems). The sequence and GenBank accession number for the forward and reverse primers used to quantify mRNA were as follows: acyl-CoA oxidase (ACOX) (AB340914) forward: 5#-CCAGTCTGAAATCAAGAGAAGCGAG-3# and reverse: 5#-AAAGTGGAA-GGCATAGGCGGTG-3#; cyclin D1 (NM_007631) forward: 5#-ACCCTGACA-CCAATCTCCTCAAC-3# and reverse: 5#-TGGATGGCACAATCTCCTTCTG-3# and cyclin-dependent kinase 4 (CDK4) (NM_009870) forward: 5#-TTGTGCA-GGTAGGAGTGCTG-3# and reverse: 5#-TGCCAGAGATGGAGGAGTCT-3#. The following conditions were used for PCR: 95°C for 15 s, 94°C for 10 s, 60°C for 30 s and 72°C for 30 s in 45 cycles. Relative expression levels of mRNA were normalized to GAPDH and analyzed for statistical significance with the Student's t-test.
Immunoblot analysis
Immunoblot analysis was carried out on liver homogenates. Proteins were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting using monoclonal anti-catalase (Sigma) or rabbit anti-peroxisomal membrane protein 70 polyconal antibodies (Abcam) as primary, anti-rabbit immunoglobulin G horseradish peroxidase as secondary antibodies (Sigma) and an enhanced chemiluminescence detection kit (Pierce, RockFord, IL). Immunoblotting with goat anti-b-actin or anti-GAPDH antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) were used as loading controls.
Data analysis
All data are presented as the mean ± standard error of mean. The differences between groups were assessed by analysis of variance. Differences were considered statistically significant at P , 0.05.
Results
Generation and characterization of the LAP-VP16PPARa transgenic mice
Northern blot analysis of liver samples revealed the expression of both endogenous PPARa and transgenic LAP-VP16PPARa mRNA in adult liver samples. The high molecular weight bands corresponding to the endogenous mouse PPARa were detected in all samples, whereas the mRNA corresponding to the transgenic VP16PPARa only appeared in LAP-VP16PPARa mice in the absence of dox ( Figure 1A ). As expected, dox repressed the expression of VP16PPARa in LAPVP16PPARa mice as noted by the absence of VP16PPARa mRNA in dox-treated LAP-VP16PPARa mice. Immunohistochemical analysis of liver sections showed that VP16PPARa proteins (detected by a VP16 antibody) were expressed only in the hepatocytes of LAPVP16PPARa mice in the absence of dox ( Figure 1B) , in contrast to the absence of VP16PPARa proteins in Wt or LAP-VP16PPARa mouse liver in the presence of dox (data not shown). Thus, by employing the tetracycline regulation system, constitutive expression of the LAPVP16PPARa transgene in mouse hepatocytes was achieved.
Hepatomegaly is one of the pleiotropic effects caused by PPs in rats and mice. Hepatomegaly was observed in LAP-VP16PPARa mice in the absence of dox as revealed by the increased liver to body weight ratio compared with Wt mice. As expected, dox treatment abolished this effect, indicating that it is due to expression of the transgene ( Figure 1C) . However, the extent of hepatomegaly in LAPVP16PPARa mice was lower than the hepatomegaly induced by 2 weeks Wy-14,643 treatment in Wt mice. Histological examination of liver sections revealed that Wt mice treated with Wy-14,643 for 2 weeks had hepatocyte hypertrophy with obvious eosinophilic cytoplasm ( Figure 1D ). In contrast, no hypertrophy and eosinophilic cytoplasms were observed in LAP-VP16PPARa mice in the absence of dox ( Figure 1D ). In addition, lipid accumulation was observed in the
liver of LAP-VP16PPARa mice in the absence of dox ( Figure 1D ). Analysis of liver lipid content indicated that the increased lipid accumulation is due to triglycerides, but not cholesterol ( Figure 1E ). As expected, dox treatment abolished this phenotype, indicating that it is due to expression of the VP16PPARa transgene.
Induction of PPARa target genes and fatty acid oxidation in the LAP-VP16PPARa transgenic mice To examine whether expression of the VP16PPARa transgene induces PPARa target genes, the expression of known hepatic PPARa target genes were examined through northern blot analysis. Compared with Wt control, the induction of genes encoding enzymes involved in peroxisomal (ACOX and bifunctional enzyme), mitochondrial (long chain acyl-CoA dehydrogenase and very long chain acyl-CoA dehydrogenase) and microsomal CYP4A3 fatty acid catabolism was observed in LAP-VP16PPARa mice in the absence of dox, and the extent of induction was comparable with Wt mice treated with Wy-14,643 for 2 weeks (Figure 2A) . Administration of dox to LAPVP16PPARa mice abolished these effects, indicating the role of VP16PPARa expression in the phenotypes observed. As these genes contain peroxisome proliferator response element binding sites in their promoter regions (23) , this result demonstrated that expression of the VP6PPARa transgene in LAP-VP16PPARa mice functions in the same manner to regulate hepatic target gene expression as PPARa activated by ligand in Wt mice.
To examine whether induction of these genes changed fatty acid metabolism, the palmitoyl-CoA oxidation activity was examined. Compared with Wt control, the induction of palmitoyl-CoA oxidation was observed in LAP-VP16PPARa mice in the absence of dox, and the extent of induction was comparable with Wt mice treated with Wy-14,643 for 2 weeks ( Figure 2B ). Administration of dox to LAPVP16PPARa mice abolished this effect, indicating that it is due to the expression of VP16PPARa. As a result, in the absence of dox, LAPVP16PPARa mice also had significantly decreased serum triglycerides ( Figure 2C ) and free fatty acids ( Figure 2D ) compared with Wt mice. These effects were comparable with Wt mice treated with Wy-14,643 for 2 weeks (Figure 2C and D) . Both effects were also abolished upon dox treatment. This indicated that expression of the VP16PPARa transgene in mouse hepatocytes is sufficient to reduce serum lipids.
Induction of peroxisome proliferation in the LAP-VP16PPARa transgenic mice
The hallmark feature of rodents administered with PPs is peroxisome proliferation. To determine whether peroxisome proliferation occurred by expression of the transgene VP16PPARa, the protein levels of the major peroxisomal membrane protein 70, a marker of peroxisome proliferation, were examined by western blot analysis. Compared with Wt control mice, a robust induction of peroxisomal membrane protein 70 was observed in LAP-VP16PPARa mice in the absence of dox; the extent of induction was similar to that observed in the Wt mice treated with Wy-14,643 for 2 weeks ( Figure 3A ). As expected, dox treatment abolished this induction, indicating that it was due to expression of the VP16PPARa transgene. In combination with the induction of genes encoding the peroxisomal ACOX and bifunctional enzyme in LAP-VP16PPARa mice (Figure 2A ), this result indicated that activation of PPARa only in hepatocytes is sufficient to induce peroxisome proliferation. As peroxisome proliferation is always associated with an induction in expression of catalase, catalase protein levels were determined by western blot analysis. An increase in catalase was observed in Wt mice treated with Wy-14,643 as compared with untreated Wt controls ( Figure 3B ). However, no changes were observed in LAP-VP16PPARa mice in the absence of dox compared with control, suggesting that activation of PPARa only in hepatocytes is not sufficient to induce catalase expression.
Induction of hepatocyte proliferation in the LAP-VP16PPARa transgenic mice
Hepatocyte proliferation is considered as a key step in PP-induced hepatocellular carcinomas. Hepatocyte proliferation was determined by measuring BrdU incorporation into hepatocyte nuclei. Immunohistochemical analysis revealed a high degree of incorporation of BrdU in livers of Wt mice after 2 weeks Wy-14,643 treatment ( Figure  4A ) with a labeling index average of 20.5% compared with 1.6% in untreated Wt controls ( Figure 4B ). In the absence of dox, LAPVP16PPARa mice also had a high degree of incorporation of BrdU ( Figure 4A ) with an average labeling index of 20.8% compared with 1.0% in LAP-VP16PPARa mice in the presence of dox ( Figure 4B ). As expected, dox treatment abolished this induction, indicating that it is due to expression of the VP16PPARa transgene. Interestingly, nonparenchymal cell (NPC) proliferation was not observed in LAPVP16PPARa mice in the absence of dox in contrast to the dramatic proliferation of these cells in Wy-14,643-treated Wt mice ( Figure 4A ). In addition, no significant increases in numbers of apoptotic cells were observed in the Wt mice treated with Wy-14,643 or in LAP-VP16PPARa mice in the absence of dox as determined by the transferase-mediated dUTP nick end-labeling assay (data not shown). These data demonstrated that administration of PPs to mice induced both hepatocyte and NPC proliferation and activation of PPARa only in hepatocytes induce hepatocyte proliferation with no evidence for NPC proliferation.
Cyclins and CDKs regulate the transit of cells through the cell cycle. These proteins were found previously to be markedly up-regulated in Wt mice treated with Wy-14,643 (24) . Consistent with this finding, a 2 week Wy-14,643 treatment was shown to cause a marked induction in the expression of various genes involved in cell-cycle control (proliferating cellular nuclear antigen, CDK1, CDK4 and cyclin D1) in the livers of Wt mice ( Figure 4C and D) . As expected, the expression of these genes was also up-regulated in LAP-VP16PPARa mice in the absence of dox and dox treatment abolished this induction. This indicated that up-regulation of cell-cycle control genes may contribute to the induction of hepatocyte proliferation by activation of PPARa only in hepatocytes.
Absence of liver tumors in aged LAP-VP16PPARa transgenic mice After long-term feeding with Wy-14,643 in the diet, grossly visible lesions were observed in 11-month-old Wt mice as expected from earlier studies (11) . However, grossly visible lesions were not found in LAP-VP16PPARa mice in the absence of dox aged over 1 year. Microscopic examination of liver sections was consistent with the gross findings, as hepatocellular carcinomas and hepatic lesions were observed in the long-term Wy-14,643-treated Wt mice, but not in .20 LAP-VP16PPARa mice at the age of over 1 year in the absence of dox ( Figure 5A) . Expression of the VP16PPARa transgene in these aged mice maintained induction of the ACOX mRNA to a similar extent as Wt mice under long-term treatment with Wy-14,643 ( Figure 5B) . Furthermore, although aged mice have a lower levels of hepatocyte proliferation, LAP-VP16PPARa mice and Wt mice after long-term treatment with Wy-14,643 had a similar induction of hepatocyte proliferation ( Figure 5C and D) . These results demonstrate that constitutive activation of PPARa in mouse hepatocytes induces hepatocyte proliferation, but is not sufficient to induce liver tumors. 
Constitutive activation of PPARa in mouse hepatocytes
Discussion
Expression of the VP16PPARa transgene in mouse hepatocytes provides a useful strategy for examining PPARa mediated effects in mouse liver. This approach has previously been used to uncover the biological functions of PPARa in skin and mammary gland development (15, 25) . LAP-VP16PPARa mice exhibited various peroxisome proliferator-induced responses including significantly decreased serum triglycerides and free fatty acids, peroxisome proliferation and marked induction of PPARa target genes encoding fatty acid b-oxidation enzymes. This indicates that activation of PPARa only in hepatocytes is sufficient to induce these effects. However, in contrast to a high degree of hepatomegaly and eventual liver tumors after long-term Wy-14,643 feeding, LAP-VP16PPARa mice exhibited only a moderate degree of hepatomegaly and no liver tumors when aged over 1 year. This demonstrates that activation of PPARa in mouse hepatocytes is not sufficient to induce liver tumors. Activation of PPARa is causally related to the induction of liver tumors in susceptible rodent species as revealed by the finding that Ppara-null mice are refractory to hepatocarcinogenesis after feeding prototypical PPs such as Wy-14,643 and bezafibrate (11, 12) . The increased oxidative stress and increased hepatocyte proliferation and/or decreased apoptosis have been proposed as key mediators of the hepatocarcinogenic effects by PPs (26) . Production of reactive oxygen species caused by sustained overproduction of H 2 O 2 by increased expression and activity of the peroxisomal enzyme ACOX in response to activation of PPARa was the earliest proposed response to be implicated in the mechanism of carcinogenesis by PPs (27) . LAPVP16PPARa mice also exhibited a robust expression of ACOX and accompanied peroxisome proliferation and palmitoyl-CoA oxidation, but had no changes in catalase protein expression in contrast to the robust induction of catalase by Wy-14,643 in Wt mice. This suggests that the oxidative stress induced by increased expression of ACOX and peroxisome proliferation is not directly responsible for the development of liver cancer. Indeed, the degree of peroxisome proliferation observed in rodents fed PPs does not always correlate with tumorigenity (28) . Development of liver tumors in mice with a disrupted Acox1 gene suggested the existence of other potential sources oxidative stress (29) . Thus, peroxisome proliferation and induction of ACOX that occurs in response to treatment with PPs appears more associative than causative in the hepatocarcinogenesis response.
Increased hepatocyte proliferation and inhibition of apoptosis were also proposed to mediate the hepatocarcinogenic effects by PPs (26) . Quite surprisingly, the BrdU incorporation study revealed that similar to Wt mice treated with Wy-14,643, LAP-VP16PPARa mice also had marked induction of hepatocyte proliferation. However, no significant changes of apoptosis were observed in both cases. In addition, induction of the cell-cycle genes such as CDK1, CDK4 and cyclin D1 by Wy-14,643 in Wt mice, which was not observed in Ppara-null mice (30) , was also observed in LAP-VP16PPARa mice. This demonstrates that activation of PPARa in hepatocytes only is sufficient to induce hepatocyte proliferation in vivo. To our knowledge, both of these cell-cycle genes are not direct PPARa target genes and thus further investigation is required to define how activation of PPARa in hepatocytes induce these genes and hepatocyte proliferation.
The increased liver weight after administration of PPs to rodents is probably the result of both hypertrophy and hyperplasia of hepatocytes. The typical hepatocyte hypertrophy and prominent eosinophilic cytoplasm induced by PPs in Wt mice were not observed in LAPVP16PPARa mice. Most interestingly, induction of proliferation of NPCs was only observed in Wt mice upon Wy-14,643 treatment, but not in LAP-VP16PPARa mice. These results suggest that the differences in hepatocyte morphology and in tumor induction between LAP-VP16PPARa mice and Wt mice treated with Wy-14,643 may be associated with the differences in activation of NPCs.
Hepatic NPCs include Kupffer cells, hepatic stellate cells and sinusoid endothelial cells. However, studies on the involvement of NPCs in peroxisome proliferator-induced liver tumor are limited. NPCs have been implicated in the hepatic proliferative response to PPs. DNA synthesis induced by nafenopin was prevented by the removal of NPCs from normal primary hepatocyte cultures and was restored by returning NPCs to the purified hepatocytes (31, 32) . Kupffer cell inhibitors such as methyl palmitate or glycine could prevent the activation of NFjB by reactive oxygen species and induction of hepatocyte proliferation in response to Wy-14,643 (33) (34) (35) . This suggests the involvement of activation of NFjB by Kupffer cells in hepatocyte proliferation caused by PP treatment in vivo. In the present study, induction of hepatocyte proliferation upon expression of activated PPARa only in hepatocytes indicates that hepatocyte proliferation induced by PPs does not require the activation of Kupffer cells, although the existence of Kupffer cells appears to be necessary to support hepatocyte proliferation. On the other hand, PPs appear to directly activate Kupffer cells in vivo (36, 37) . The oxygen radicals produced by activated Kupffer cells may contribute to the oxidative stress that in turn may be responsible for the initiation of hepatocarcinogenesis.
Understanding the mechanism of PP-induced carcinogenicity in rodents will allow the evaluation and comparison with possible mechanisms in humans that will be of great value in human risk assessment. The LAP-VP16PPARa mouse model described in this study provides a tool to investigate the carcinogenic mechanisms that act through PPARa. In addition, this mouse model should also facilitate examination of the pleiotropic effects induced by PPs on various physiological responses during development.
